"Recent regulatory changes in antidepressant labels: Implications for activation (stimulation) in clinical practice." Primary Psychiatry, 13, 57-60, 2006.
"Recent U.S., Canadian and British regulatory agency actions concerning antidepressant-induced harm to self and others: A review and analysis." Ethical Human Psychology and Psychiatry, 7, 7-22, 2005. Simultaneously published in the International Journal of Risk and Safety in Medicine, 16, 247-259, 2005.
Risks and Mechanism of Action of Stimulants. NIH Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, November 16-18, 1998.
"Shock Treatment III: Resistance in the 1980's." Electroshock: The Case Against, Dr. Robert F. Morgan, editor. Morgan Foundation Publishers, Fair Oaks, CA. pp. 43-56. 1999.
"Should the Use of Neuroleptics Be Severely Limited?" In S.A Kirk and Susan D. Einbinder P (ed): Controversial Issues in Mental Health. Boston: Allyan and Bacon, 1994, pp 146-152. Reprinted in Changes: An International Journal of Psychology and Psychotherapy 14:62-66 March 1996.
"Spearheading a Transformation." Co-published simultaneously in The Psychotherapy Patient (The Hawthorn Press, Inc.) Vol.9, No. 3/4, pp. 1-7, 1996; and: Psychosocial Approaches to Deeply Disturbed Persons, P. Breggin and E. Stern, editors, The Hawthorn Press, Inc., 1-7, 1996.
"Suicidality, Violence and Mania Caused by Selective Serotonin Reuptake Inhibitors (SSRIs): A Review and Analysis." International Journal of Risk and Safety in Medicine, 16: 31-49, 2003/2004. Originally published in Ethical Human Sciences and Services, 5:225-246.
“TBI, PTSD, and psychiatric drugs. A perfect storm for causing abnormal mental states and aberrant behavior.” In Brock, H. and Else, R.C. (Eds). The Attorney’s Guide to Defending Veterans in Criminal Court. Minneapolis, MN: Veterans Defense Project. Chapter 10, pp. 251-264, 2014.
Peter R. Breggin, MD
Recent years have seen a marked increase in the prescription of psychiatric drugs to activity duty military personnel and to veterans. Until the Iraq and Afghanistan wars, soldiers were rarely if ever sent into combat while taking psychiatric drugs, but now it is commonplace, and may occur in 20% or considerably more of combat troops. Nearly all soldiers returning from combat with psychiatric diagnoses will be placed on multiple psychiatric drugs and maintained on them during treatment at the VA.
International Journal of Risk & Safety in Medicine 22 (2010) 89-92.
Peter R. Breggin
Abstract: Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the FDA. The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury”, which would have required their testing before approval. Without requiring this testing, the FDA is now preparing to classify the treatment and the machines as safe. This article reviews evidence demonstrating that ECT is very harmful to the brain and mind, and concludes that the FDA should demand the usual testing, starting with animals, that is required before psychiatric treatments and machines are approved for marketing and use.